Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3 Melanoma 2 Carcinoma, Non-Small-Cell Lung 2 Adenocarcinoma 2 Sarcoma, Clear Cell 1 Rectal Neoplasms 1 Radiation-induced Oral Mucositis 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Platinum-resistant Epithelial Ovarian Cancer 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Anatomic Stage I Breast Cancer AJCC v8 1 Adenocarcinoma of Lung 1

Interventions

Sorafenib 26 Nivolumab 21 pembrolizumab 15 Bevacizumab 14 lenvatinib 12 atezolizumab 9 Cyclophosphamide 9 Ipilimumab 8 durvalumab 6 camrelizumab 5 apatinib 5 Specimen Handling 5 Radiosurgery 5 tislelizumab 4 fludarabine 4 Immunotherapy, Adoptive 4 Fluorouracil 4 Doxorubicin 4 tremelimumab 3 toripalimab 3 sintilimab 3 regorafenib 3 cabozantinib 3 X-Rays 3 Magnetic Resonance Spectroscopy 3 Injections 3 Everolimus 3 Ethiodized Oil 3 Erlotinib Hydrochloride 3 tepotinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Hepatocellular × Hydroxychloroquine × Clear all

NCT05842174 2026-04-16

TAQE

VA Office of Research and Development

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡